Recent AD treatments have focused on inhibiting tau hyperphosphorylation by slowing the progression of tauopathies, but we still do not fully understand the mechanism behind tauopathies and its toxicity on neurological functions [8]. This evidence concerns the gene MAPT and tauopathy.